Cargando…
Risk–Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults
Purpose: To estimate the risk–benefit trade-off of a pediatric-inspired regimen versus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) for first-line treatment of adolescents/young adult (AYA; ages 16–39 years) patients with Philadelphia-negative acute ly...
Autores principales: | Guzauskas, Gregory F., Villa, Kathleen F., Vanhove, Geertrui F., Fisher, Vicki L., Veenstra, David L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346961/ https://www.ncbi.nlm.nih.gov/pubmed/27779442 http://dx.doi.org/10.1089/jayao.2016.0049 |
Ejemplares similares
-
Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
por: Gui, Lin, et al.
Publicado: (2021) -
The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.
por: Wardley, A. M., et al.
Publicado: (1998) -
Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery
por: Tennvall, J, et al.
Publicado: (2002) -
Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021) -
Successful treatment of an elderly Langerhans cell sarcoma patient by EPOCH
(etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin)
chemotherapy
por: Matsukawa, Toshihiro, et al.
Publicado: (2018)